Advanced Purchase Agreements for Covid-19 Vaccines: Do they ensure Global Public Good?
Advanced Purchase Agreements (APAs) were part of a strategy to provide upfront financing for Covid-19 vaccines and to accelerate their development and availability. Since...
Something is going terribly wrong with the EU Compulsory Licensing Regulation
This week the European Parliament will vote on amendments to the Commission’s proposed regulation of the European Parliament and the Council on compulsory licensing...
Covid-19 intellectual property pool gaining support
While drug and vaccine developers are working on tools to prevent and treat Covid- 19, here is a question the rest of us should...
The new IP strategy of war-torn Ukraine should prioritise public health and national security
Russia’s full-scale assault on Ukraine continues for the third year. The Russian occupation forces have already killed tens of thousands of civilians, including children. They have...
UN “Pact for the Future” intellectual property actions need revision to ensure innovation and...
UPDATE: From 22-23 September 2024, the Summit of the Future took place and adopted the Pact for the Future. The intellectual property paragraph of...
World Health Organization Members ask for more time to solve difficult negotiations on access...
World Health Organization member states will propose to continue negotiations on a critical annex to the Pandemic Agreement, after being unable to bridge key...
Wrapping up 2025: A tumultuous year for global public health law & policy
The end of 2025, a tumultuous year for global public health, is here, and it’s time for the usually highly biased Medicines Law &...
Pharmaceutical Pricing Hostages
Ireland seems to be the stage of some of the most bizarre pharmaceutical company behaviour these days. This month, the pharmaceutical company CSL Behring...
Humiragate: AbbVie’s desperate attempts to keep its monopoly
A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...
The Waiver that Wasn’t: Is the pharma lobby responsible?
Systemic lobbying pressure from pharmaceutical companies – allegedly attached to threats to withdraw investments – may have been responsible for the watering down of...